A 24-week phase III study to evaluate the efficacy and tolerability of beclometasone/formoterol single inhaler HFA [hydrofluoroalkane] 134a-pMDI [pressurised meter dose inhalers] in adult patients with moderate to severe persistent asthma.

Trial Profile

A 24-week phase III study to evaluate the efficacy and tolerability of beclometasone/formoterol single inhaler HFA [hydrofluoroalkane] 134a-pMDI [pressurised meter dose inhalers] in adult patients with moderate to severe persistent asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Beclometasone; Formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 01 Jan 2009 Results were published in Repiratory Medicine in Jan 2009.
    • 21 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top